Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by The Hospital for Sick Children.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
The Hospital for Sick Children
ClinicalTrials.gov Identifier:
NCT01001871
First received: October 21, 2009
Last updated: October 26, 2009
Last verified: October 2009

October 21, 2009
October 26, 2009
November 2009
October 2010   (final data collection date for primary outcome measure)
incidence of clinical malaria (if fever recorded a blood sample will be taken to determine parasite species and count) [ Time Frame: 5 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01001871 on ClinicalTrials.gov Archive Site
  • changes in anemia status (blood levels of: haemoglobin(Hb) , ferritin (SF)) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • severity of clinical malaria (blood parasite count) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • cerebral malaria (defined by a parasite count >5000/μL blood and a concurrent score of <2 on the Blantyre coma scale, with or without convulsions) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • hospitalization (documentation of hospitalization for any reason) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • death [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • pneumonia (defined by the presence of a cough or breathing difficulties, tachypnea, lower chest wall indrawing, and the appearance of consolidation or pleural effusion on a chest X-ray) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • diarrhea (defined by >3 loose or watery stools in the previous 24 hours) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
  • dehydration (defined by lethargy, sunken eyes, and decreased skin turgor [>2 seconds for skin to return following a skin pinch]) [ Time Frame: 5 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana
Seasonal Impact of Iron Fortification on Malaria Incidence in Ghanaian Children

Iron deficiency and iron deficiency anemia (IDA) are the most prevalent micronutrient deficiencies on a worldwide basis, especially in developing countries. The impact of severe IDA can have mortal consequences, since without adequate hemoglobin, the brain and body become deprived of oxygen and, if allowed to continue, death may ensue. It has been shown that iron supplementation in infants and young children can enhance child development, however, it may also result in increased rates of malaria in high burden areas.

The primary objective of this study is to determine the impact of providing encapsulated iron (as a powder added to complementary foods) on the susceptibility to clinical malaria among anemic and non-anemic infants and young children (6-24 months of age) living in a high malaria burden area.

The value of performing this research in Ghana is primarily that malaria and anemia remain the most important causes of death and morbidity.

Study Design:

The proposed study is a community-based blinded randomized controlled trial with 2 study arms that will be conducted in two phases:

  • Phase I will take place during the dry season (December to April), when malaria transmission rates are lower. Eligible subjects (one per household) will be individually randomized to receive a daily dose of either a powdered vitamin/mineral fortificant containing 12.5 mg of iron (plus ascorbic acid, vitamin A and zinc), or a placebo (containing all micronutrients excluding iron), added to complementary foods, for 5 months.
  • Phase II will take place during the wet season (June to October), when malaria transmission rates are higher. Eligible subjects, who did not participate in Phase I, will be individually randomized to one of the two study arms as described above and followed for 5 months.

A dual phase design, with two unique cohorts, was chosen so that preliminary results (at the end of phase 1) could be assessed by an independent Data Safety and Monitoring Committee. It is possible that during the dry season no impact of iron will be detected, while during the wet season, an impact will be observed. With this possible outcome, it is potentially feasible to translate this knowledge into a Ministry of Health Program to only provide iron supplementation (fortification) during the dry months of the year (December to April).

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Anemia
  • Dietary Supplement: Sprinkles®
    powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
  • Dietary Supplement: vitamin/mineral fortificant without iron
    powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
  • Experimental: Vitamin/mineral fortificant with iron
    Intervention: Dietary Supplement: Sprinkles®
  • Placebo Comparator: Vitamin/mineral fortificant without iron
    Intervention: Dietary Supplement: vitamin/mineral fortificant without iron
Zlotkin S, Newton S, Aimone AM, Azindow I, Amenga-Etego S, Tchum K, Mahama E, Thorpe KE, Owusu-Agyei S. Effect of iron fortification on malaria incidence in infants and young children in Ghana: a randomized trial. JAMA. 2013 Sep 4;310(9):938-47. doi: 10.1001/jama.2013.277129.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
3880
May 2011
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 6-24 months
  • Ingesting weaning food in addition to breastmilk
  • Free from malaria or other major illnesses
  • Afebrile
  • Living in Brong Ahafo Region of Ghana for duration of intervention and follow-up

Exclusion Criteria:

  • Severe anemia (hemoglobin <70g/L)
  • Weight-for-height <-3 z-score(severe wasting)
  • Kwashiorkor (defined as evidence of edema)
  • Congenital abnormality
  • Treatment with iron supplements within the past 6 months
  • Presence of any chronic illness
Both
6 Months to 24 Months
Yes
Contact: Stanley Zlotkin 416-813-6171 stanley.zlotkin@sickkids.ca
Ghana
 
NCT01001871
1000013476
Yes
Stanley Zlotkin/Principal Investigator, The Hospital for Sick Children
The Hospital for Sick Children
Not Provided
Principal Investigator: Stanley H Zlotkin, PhD The Hospital for Sick Children, Toronto, Canada
The Hospital for Sick Children
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP